Isabelle Mahé: Cancer Site, Bleeding Risk, and Reduced-Dose Apixaban in Cancer-Associated Thrombosis
Isabelle Mahé, Head of Internal Medicine at Louis Mourier Hospital, APHP at Paris Cité University, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Bleeding risk varies according to solid cancer site, with a low risk of CRB in breast cancer (6·2%) and a narrow range across other solid tumours (15·4–18·5%) (original Article recently published in The Lancet Haematology)
Please read our reply just published in The Lancet Haematology!
In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding (APICAT study published in NEJM Group)”
Title 1: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology
Title 2: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J. López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V. Huisman, Frederikus A. Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T. Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 8, 2026, 06:30Caryn Blumenfeld: Team Zakophilia and Ratner’s Runners Even Though It’s A Walk!
-
Jun 8, 2026, 06:25Cécile Jefford: The NEHA Community and the Power of Human Connection
-
Jun 8, 2026, 06:02Manoj K: How Incyte Could Help Transform Care for Patients With von Willebrand Disease
-
Jun 8, 2026, 03:05Shamsunisha Yusuff: Iron Down, Platelets Up in a Young CBC ?
-
Jun 8, 2026, 03:03Samwel Mikaye: D-Dimer – A Marker of Blood Clot Breakdown
-
Jun 8, 2026, 02:59Vinita Madhuri: Our Engagement, A Lifeline for Thalassemia Patients
-
Jun 7, 2026, 22:11Lucia Härtel: Exercise, IL-10 Signaling, and Post-Stroke Brain Plasticity
-
Jun 7, 2026, 19:35Ashish Pemawat: Is the 4.5-Hour Thrombolysis Window Becoming Less Relevant?
-
Jun 7, 2026, 18:25Nita Radhakrishnan: Every Child Cured Is a Reminder of What Can Be Achieved When We Work Together